![]() | ![]() |
Formats:
|
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Copyright : © 2007 Talavera et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. The (In)dependence of Alternative Splicing and Gene Duplication Philip E Bourne, Editor 1 Molecular Modeling and Bioinformatics Unit, Parc Científic de Barcelona, Barcelona, Spain 2 Protein Structure and Modelling Node, Instituto Nacional de Bioinfomática, Genoma España, Parc Científic de Barcelona, Barcelona, Spain 3 Medical Research Council Laboratory of Molecular Biology, Cambridge, United Kingdom 4 Institute for Cellular and Molecular Biology, University of Texas Austin, Austin, Texas, United States of America 5 Departament de Bioquímica i Biologia Molecular, Universitat de Barcelona, Barcelona, Spain 6 Computational Biology Program, Barcelona Supercomputing Center, Barcelona, Spain 7 Institut per a la Recerca i Estudis Avançats (IRCA), Barcelona, Spain University of California San Diego, United States of America #Contributed equally. * To whom correspondence should be addressed. E-mail: xavier/at/mmb.pcb.ub.es (XdlC); Email: cvogel/at/mail.utexas.edu (CV) Received June 30, 2006; Accepted January 4, 2007. This article has been cited by other articles in PMC.Abstract Alternative splicing (AS) and gene duplication (GD) both are processes that diversify the protein repertoire. Recent examples have shown that sequence changes introduced by AS may be comparable to those introduced by GD. In addition, the two processes are inversely correlated at the genomic scale: large gene families are depleted in splice variants and vice versa. All together, these data strongly suggest that both phenomena result in interchangeability between their effects. Here, we tested the extent to which this applies with respect to various protein characteristics. The amounts of AS and GD per gene are anticorrelated even when accounting for different gene functions or degrees of sequence divergence. In contrast, the two processes appear to be independent in their influence on variation in mRNA expression. Further, we conducted a detailed comparison of the effect of sequence changes in both alternative splice variants and gene duplicates on protein structure, in particular the size, location, and types of sequence substitutions and insertions/deletions. We find that, in general, alternative splicing affects protein sequence and structure in a more drastic way than gene duplication and subsequent divergence. Our results reveal an interesting paradox between the anticorrelation of AS and GD at the genomic level, and their impact at the protein level, which shows little or no equivalence in terms of effects on protein sequence, structure, and function. We discuss possible explanations that relate to the order of appearance of AS and GD in a gene family, and to the selection pressure imposed by the environment. Author Summary Alternative splicing (AS) and gene duplication (GD) followed by sequence divergence constitute two fundamental biological processes contributing to proteome variability. The former reflects the ability of many genes to express different products, while the latter results in several copies of the same gene that are similar but not identical. In spite of these obvious differences, recent computational studies as well as anecdotal experimental evidence suggested that AS and GD produce functionally interchangeable protein variants. We provide a detailed study of the differences between alternative splicing and gene duplication and discuss potential interchangeability with respect to variation in expression, protein structure, and function. In general, the contribution of these two processes to the proteome variability is substantially different, and we advance some explanations that may explain this apparent contradiction and contribute to our understanding of the evolution of complex, eukaryotic proteomes. Introduction Alternative splicing (AS) and gene duplication (GD) are two main contributors to the diversity of the protein repertoire with enormous impact on protein sequence, structure, and function [1–5]. Interestingly, several recent studies point to a direct equivalence between AS and GD. There are some cases where alternative splice variants in one organism are similar to gene duplicates in another organism [6–9]. For example, the eukaryotic splicing factor U2AF35 has at least two functional splice variants in human, U2AF35a and U2AF35b, which differ by seven amino acids in the RNA recognition motif (Figure 1
Further, the changes introduced to a sequence are constrained by the need to preserve a stable and functional three-dimensional (3-D) fold [10]. Indeed, structural studies have shown that insertions and deletions between gene duplicates tend to happen at sequence locations where they are less damaging [11], such as loops at solvent-accessible locations. These restrictions will apply irrespective of the source of the changes and thus may introduce a certain degree of similarity between the sequence changes associated with GD and AS. Finally, recent studies have shown that AS and GD are inversely correlated on a genome-wide scale [12,13], i.e., small gene families tend to have more genes with alternative splice variants than do large families. These findings together—i.e., anecdotal examples, structural constraints, and anticorrelation at the genomic level—suggest that AS and GD are interchangeable sources of functional diversification [12]. Genes with AS would not need to produce additional variants in the form of duplicates, and vice versa. Here, we first tested the anticorrelation between AS and GD with respect to sequence divergence, function, and gene expression. Second, we studied the interchangeability hypothesis at the protein structure level and asked to what extent AS and GD introduce changes to the sequence that are equivalent in their nature and effect on structure and function. To this end, we conducted a large-scale comparison of the effects of AS and GD on human and mouse proteins (Figure 1 Results/Discussion Genomic Analysis In accordance with recent findings [12,13], AS and GD are anticorrelated at the genomic level (Figure 2 0.001 in both cases) than amongst human–yeast orthologues (GD80, χ2-value = 84; p-value 0.001).
Gene function. The anticorrelation between AS and GD could arise from the preferential duplication or introduction of AS in genes of particular function. In general, genes with AS have similar distributions across functional categories as genes with GD (see Table S3, Figure S2), with two exceptions. Ribosomal and receptor proteins (e.g., G protein–coupled receptors) belong to the largest protein families in human [14], and thus their enrichment in families of GD is unsurprising (E-value < 10−10). At the same time, these functions are depleted amongst genes with alternative splice variants [15], which is also reflected in our data (E-value < 10−10). When removing from our dataset the 855 and 293 proteins predicted to be G protein–coupled receptor-like or ribosomal proteins [14], respectively, the bias against genes with both AS and GD (AS+/GD+) is still strongly significant (p-value 0.001). See Table S3 for details. Thus, the anticorrelation between AS and GD is not due to biases amongst genes of different functions.Variation in expression patterns. We further characterized the relationship between AS and GD by comparing their patterns of expression among different tissues, which reflect corresponding regulatory processes. A previous study reported that AS and general transcription regulation act independently on different groups of genes with tissue-specific expression [16]. Here we do not compare tissue specificity, but the overall extent of variation in expression introduced by AS and GD. More precisely, we studied whether the extent of coexpression (i.e., the lack of expression variation) between alternative splice isoforms is comparable to that found between duplicates (Figure 2 The level of coexpression was measured using the Pearson correlation coefficient (PC) between the expression patterns of two isoforms among a set of tissues, in the case of AS, or of two duplicates, in the case of GD. When more than two isoforms (or duplicates) were available, we averaged the PCs resulting from all the possible comparisons between them (see Material and Methods and Figure S10). PC values near 1 or 0 correspond to high or low coexpression, respectively. We directly compared the coexpression in alternative splice variants (AS coexpression) and in gene duplicates (GD coexpression) using data from the same microarray experiment [17] (white diamonds in Figure 2 We also explored whether we can observe, at the expression level, an anticorrelation in analogy to that found at the sequence level [12,13] (Figure 2 We note that the coexpression analysis is at present still limited by the amount of data available. Future availability of large-scale datasets suited for expression comparison of AS and GD will help refine our results. Protein Sequence and Structure Analysis To test whether AS and GD are interchangeable at the structural and thus functional level, we compare sequence changes between duplicate proteins to those between alternative splice isoforms (Figure 1 We focus on gene families defined using two seq.id. thresholds: 80% and 40%. The former was chosen because the anticorrelation at the genomic level is stronger (Figure 2 Substitutions First we examine substitutions, i.e., the extent and nature of amino acid changes and the length of the substituted region. In general, substitutions amongst GD range from a small number of amino acid replacements in recent homologues to a large number of replacements in proteins as divergent as haemoglobin, for instance [10]. In AS, substitutions in one isoform as compared with another one arise by the use of mutually exclusive exons [20], although they can also be due to intron retentions accompanied by stop codons [21]. Global versus local sequence identity. Global seq.id. is the seq.id. along the whole alignment of two sequences, and it can be used to assess the overall degree of function conservation between proteins [22]. However, same global seq.id. values may correspond to very different distributions of amino acid replacements along the sequence. For this reason, we also examined local seq.id., i.e., the seq.id. between only parts of two sequences. For alternative splice variants, the local seq.id. corresponds to substituted regions, i.e., mostly mutually exclusive exons. For GD, we estimated the corresponding sequence stretches by different methods as described below. In Figure 3
In contrast, while the local seq.id. in alternative splice variants is usually low, it is clearly higher for GD, in particular for GD80 families (Figure 3 Global and local seq.id. provide a first view on interchangeability between AS and GD. However, to understand the effects of substitutions, it is also important to know the location of the changes [23,24]. To retrieve such information, we directly compared seq.id. between substituted regions in AS with the equivalent regions of their gene duplicates (AS+/GD+, Figure 3 In general, we find that the distribution of amino acid replacements along the protein sequence is different between AS and GD substitutions. In gene duplicates, changes are spread all over the sequence, while in alternative splice variants the changes are concentrated at very precise locations, in accordance with the underlying molecular mechanisms [20,21]. In general, these data point to a noninterchangeability between AS and GD changes. However, when the sequence divergence between duplicates is large, as is the case for GD40 families, there may be some cases for which AS and GD changes have comparable impact on protein function. The comparisons described above have been derived from gene families with alternative splice variants and gene duplicates (AS+/GD+, Figure 3 The nature of the sequence changes. To complete our analysis of substitutions, we compare the nature of the amino acid replacements in AS and GD, focusing on nonconservative replacements. These involve amino acids of very different physico–chemical properties, and are thus more likely to alter protein structure, stability, and function [25,26] We find that, in general, the percentage of nonconservative amino acid replacements is higher for AS than for GD substitutions, a situation that holds whether we consider GD families at the 80% (58% and 44% nonconservative replacements for AS and GD, respectively) or 40% seq.id. level (60% and 43% nonconservative replacements for AS and GD, respectively). Thus, AS substitutions are physico–chemically more aggressive than GD substitutions. Further, we use the maximal distance between replacements as a measure of the distribution of nonconservative changes along the sequence. We find clear differences between AS and GD (Figure 4
Insertions and Deletions Size. Second, we studied indels, which modify protein structure in a different way than substitutions. A first and intuitive measure of their impact is provided by indel size: small indels are more likely to have a small effect on structure than larger ones. We find that indel sizes are substantially different for AS and GD (Figure 6
Location of indels. Given that, in general, sequence changes are severely constrained by structure and stability requirements [10], it seems difficult to rationalize how AS and GD indels can be so different. A detailed explanation can only come from the structure comparison of many pairs of alternative splice isoforms for which we still lack data [31–33]. Nonetheless, a reasonable approximation can be obtained following simple considerations. The N- and C-termini usually occur at the protein surface [34]. At the terminus, inserting or deleting a sequence stretch is likely to have less of an effect on the protein's structure than internal indels, and thus external indels may be less restrained in their size. We separated the AS and GD indels according to their location in sequence (N-/C-terminal ends or internal) and plotted the corresponding size distributions (Figure 6 Overlap between indels in AS and GD. We also examined the overlap between the location of indels in splice variants and in duplicates of the same gene (Figure 7
There is also a small fraction of instances (~15%) with an obvious overlap between AS and GD indels (Figure 7 In summary, the results obtained in the study of indels lead to the same conclusions as for substitutions: in general, the impact of AS and GD on protein function is not interchangeable, irrespective of whether we consider GD at the 80% or 40% seq.id. levels. Conclusions and Possible Explanations of the Inverse Correlation between AS and GD AS and GD are anticorrelated at the genomic level (Figure 2
To explain the apparent paradox between the relationship of AS and GD at the genome and at the protein level, we speculate on alternative explanations for the depletion of AS observed in large GD families (Figure 2 Finally, if a gene with AS has duplicated, subsequent loss of an isoform in one of the copies may be tolerated due to the existence of an identical version of this isoform in the other copy of the gene. This explanation is supported by recent findings on the evolution of AS upon GD [13], and the fact that the depletion in AS is stronger for closely related duplicates [12,13] (Figure 2 A combination of these effects would, in general, result in a smaller proportion of genes with AS in gene families with more than one duplicate, in particular for recent duplicates, suggesting that the chronological order of events plays a role. Subsequent divergence of the gene duplicates may alleviate the negative impact of the dosage balance effect, allowing the evolution of AS and reducing the anticorrelation between AS and GD. Materials and Methods Genomic Analysis Datasets. To test the relationship between GD and AS at the genomic level, we used: (i) clusters of homologous sequences inferred from the seq.id. (equivalent to gene families); (ii) sets of known or predicted alternative splice variants, or isoforms, for a particular gene. An overview of the data is provided in Table S1. For AS genes, we primarily used the datasets downloadable from EBI AltSplice server (releases 2.0 for both mouse and human) [43]. In addition, we compared the findings using the AltSplice dataset with findings using data from the SwissProt database [44] and the Ensembl predictions of splice variants [45] (see Table S1). Genes that have more than one transcript variant in either one of the three sets are denoted AS+. A small number of false positives can be expected in each of the three AS+ sets. Within the set of sequences without AS (AS−), we expect a fraction of false negatives, that is, genes that splice alternatively but for which we have no data yet. However, it is unlikely that these false positives or false negatives coincide across each dataset, as each database used its own approach to derive the data, and we expect no systematic error. All three datasets show the same trends (see Table S1), consistent with previous findings [12,13]. To estimate GD, we used the Ensembl protein predictions for human (version 37.35j) and mouse (version 37.34e) (Table S1). Both genomes were made nonredundant in that we only included the longest, predicted transcript for each gene, and the sequences were filtered for low-complexity regions using the seg program [46]. To obtain families of paralogous genes, the sequences were clustered to 40%, 60%, 80%, and 90% seq.id. using CD-HIT [47]. The higher the seq.id. cutoff for a family, the more conserved are the family members: clusters of 40% seq.id. are expected to be larger and contain more distantly related sequences than clusters of 80% seqid. Clusters with more than one sequence are termed GD+, denoting the existence of homologues. Figure S1 shows the distribution of human sequences across GD families of different sizes, using a variety of seq.id. cutoffs. The human–yeast, human–fly, and human–mouse orthologues were derived from the InParanoid database [48]. Retrotransposition creates gene duplicates that have only a single exon, and hence are unlikely to show any AS. To test for a possible bias in GD families (GD+) stemming from retrotransposition, we examined the distribution of single-exon genes across AS and GD sets using the SEGE database [49], similar to an approach described by Kopelman and colleagues [12]. The procedure followed was: (i) all human genes were clustered according to 80% seq.id.; (ii) all genes were labelled according to their known AS; and (iii) the number of single-exon genes [49] amongst singletons, gene families, and genes with/without AS was calculated. This distribution across genes with AS and/or GD is shown in Table S2. If retrotransposition was a major source of GD without AS (AS−/GD+), then we would expect to see a bias towards single-exon genes in this category. This is not the case; also see Kopelman et al. [12]. Function analysis. To determine whether the inverse relationship between AS and GD is specific to genes of particular functions, we analyzed functions for human proteins of the four different sets of genes with or without AS or GD (AS+/GD+, AS+/GD−, AS−/GD+, AS−/GD−). We analyzed gene functions from both the SwissProt and the AltSplice database using the DAVID Web server (http://david.abcc.ncifcrf.gov/home.jsp) [50]. DAVID analyzes human proteins for biases in terms of Gene Ontology [51] terms, protein domains, pathways, functional categories, protein interactions, disease, literature, and general annotations (sequence features). As a background list for comparisons, we used the union of the four sets described above. The detailed results are listed in Table S3. Expression analysis. In this part of our work, we compared the extent of coexpression between alternative splice isoforms (AS coexpression) with that of coexpression between gene duplicates (GD coexpression). To estimate AS coexpression across human genes, we analyzed data on absolute expression levels of exon junctions of 3,840 human genes, measured across 44 different tissues [17] (Geo [52] GDS829–GDS834). AS coexpression of a gene was measured as the average pairwise PC between the expression vectors of all its exon junctions. A high PC indicates low coexpression (low variation) amongst the exon junctions and hence splice variants, and vice versa. The expression of all exon junctions of a particular gene was then summarised (averaged) to form one vector representing the overall expression pattern of a gene. We measured GD coexpression of a GD family, i.e., the amount of coexpression amongst gene duplicates, as the average pairwise PC between the gene expression vectors of all family members. For gene families of >80% seq.id., the 3,840 genes in the dataset [17] did not provide enough families with more than two members to be suitable for further analysis. Thus, we examined another dataset with absolute expression values of human genes across 79 different tissues published by Su et al. [53] (Geo [52], GDS596). In contrast to the first dataset, GDS596 reports expression per gene and not per exon junction, and thus is only suited for analysis of GD coexpression, not AS coexpression. AS+ genes were defined as given by the AltSplice database [43]. Please refer to Table S4 for analysis of a third dataset, use of other measures of coexpression, and different post-processing procedures of the expression data. Protein Sequence Analysis Datasets. We assessed GD at the whole-gene level in which two proteins are assigned to the same gene family when their seq.id. is above 40%, or above 80% (GD40 or GD80, respectively). These families were obtained by clustering the SwissProt [44] human proteins using the program CD-HIT [47] (http://bioinformatics.burnham-inst.org/cd-hit). We also used the Pfam [54] domain families as a model of highly diverged gene families. More precisely, we used all the Pfam [54] families that mapped to one or several of the SwissProt [44] proteins in the AS dataset. The results obtained with this model are shown in Figure S5. To allow proper testing of the interchangeability, we focused on AS+/GD+ families, i.e., those families for which at least one gene duplicate and one splice variant are known. Our set of genes with AS was obtained after querying the SwissProt database [44] version 40, with the keywords VARSPLIC and HUMAN, or MOUSE, respectively. A summary of the number of genes, isoforms, and duplicates in the datasets used in this work is given in Table S5. SwissProt [44] is a high-quality, manually curated database that has been recently used by different research groups in the study of AS at the protein level [20,27,28,31,55–57]. While the data may be biased by the curation process, several facts suggest that this potential bias would not affect our results. First, the proportions of isoforms showing indels and substitutions in our sample, 73% and 27%, respectively, are comparable with those inferred from other studies: 76% and 24% [58], and 67% and 33% [59]. Second, the anticorrelation observed between AS and GD [12,13] (Figure 2 For all of the distributions shown in the different figures, we computed the confidence interval corresponding to each proportion in the distribution, following Goodman [63]. Characterization of substitutions. Our work involves detailed comparison between AS and GD sequence changes which occur between alternative splice isoforms or between gene duplicates (Figure 1 Global and local seq.id. Global seq.id. corresponds to the commonly used percentage of seq.id. between aligned sequences. It was computed from a whole-sequence alignment between the sequences of either two duplicates or two alternative splice isoforms, using standard dynamic programming [64]. When comparing alternative splice isoforms, one of the sequences was always that of the SwissProt [44] reference isoform. Local seq.id. refers to the seq.id. between parts of the sequences. Local seq.id. between alternative splice isoforms was always computed in the same way, comparing the sequence stretches substituted between them. To this end, we first obtained the location of these stretches from SwissProt [44], and then we aligned them using a standard dynamic programming method [64]; the local seq.id. was computed from this alignment. To avoid meaningless comparisons, we introduced some restrictions [56]: (i) both sequence stretches must be >10 aa, and (ii) the size of the shorter stretch must be at least 60% that of the larger stretch. These filters were only applied when computing the local seq.id. but for no other variable. To obtain local seq.id. between gene duplicates, we distinguished two cases (Figure S9): either we observe both AS and GD for a given gene (AS+/GD+), or we only observe GD but not AS (AS–/GD+). In AS+/GD+ cases, we followed two different procedures. The first one uses a sliding window of the size of the AS substitution, N (Figure S9A). For each gene, we then (i) aligned the sequence of the SwissProt reference sequence for the gene (usually that of the longer isoform) with that of one of the gene duplicates; (ii) computed the identity percentage between positions i and i + N − 1, at all possible i locations of the window along the alignment; and (iii) repeated steps (i) and (ii) for each comparison between the first gene and any of its duplicates. N, the size of the window, and the AS substitution were obtained from SwissProt annotations [44] (Figure 3 In the second procedure analysing the AS+/GD+ case (Figure S9B), we studied interchangeability of sequence changes at the AS location. To this end, we first aligned the sequence of the protein with known splicing to one of its duplicates. The former was always the sequence of the SwissProt [44] reference isoform. Then, we mapped location and length of the AS substituted stretch to the sequence of the gene duplicate and computed seq.id. between both sequence stretches. The information on the location and length of the AS substituted stretch was obtained from the SwissProt [44] annotations (Figure 3 In AS−/GD+ cases, a direct comparison between AS and GD local seq.id. is no longer possible. Here, local seq.id. was estimated using a moving window of size N: (i) we aligned the sequences of the two duplicates, and (ii) we computed the identity percentage between the positions i and I + N – 1, at all possible locations i of the moving window along the alignment. We calculated these local seq.id. for GD using N = 100 aa; the resulting distribution is shown in Figure 3 Nonconservative changes. We define nonconservative changes as those for which the corresponding value of the Blosum62 [65] substitution matrix is negative. This criterion has been used in the annotation of SNPs [66]. The fraction of nonconservative mismatches between two sequences was obtained by dividing the number of mismatches with a negative Blosum62 value by the total number of mismatches in the alignment. The percentages of nonconservative mismatches for AS and GD substitutions were compared using the T-test (http://home.clara.net/sisa). Distribution of the maximal distance between nonconservative mismatches. The maximal distance between mismatches corresponds to the sequence separation between the two most distant mismatches in a sequence alignment. In the case of GD, we (i) aligned all the sequences of a given gene family with the reference sequence of the member (or members) that has AS; (ii) for each alignment, mapped the mismatches to the sequence which is the reference isoform in SwissProt; (iii) for each alignment, computed the distance between the two most separated mismatches as follows: (jr – ir)/Nr, where jr and ir are the sequence locations of the closest mismatches to the C- and N- termini, respectively; Nr is the size of the latter; and (iv) repeated steps (ii)–(iii) for all the alignments obtained in (i) and binned the resulting values. In the case of AS, the maximal distance between mismatches was computed using the same equation as before: (jr – ir)/Nr, where in this case jr and ir correspond to the locations of the end and beginning of the substituted fragment, as provided by SwissProt. Note that the maximal mismatch distance was normalized by the sequence length to allow comparison of all results independent of the protein size. Comparative modeling. The structure of mitogen-activated protein kinase 9 was modelled using that of mitogen-activated protein kinase 10 [67]. The seq.id. between both proteins is 84%, which guarantees a good modelling result. The alignment between the two protein sequences was generated employing standard dynamic programming [64]. The resulting alignment was used as input to run the comparative modelling program MODELLER [68]. Characterization of indels. For all the variables, we conducted a comparison between AS and GD as described before (Figure 1 Indel sizes. The indel size distribution for the AS events was obtained from the SwissProt [44] records of the proteins in our dataset. The procedure was: (i) records with VARSPLIC annotations were parsed for the presence of MISSING annotations; (ii) the MISSING annotation provided the initial (M) and final (N) positions of the inserted/deleted fragment; and (iii) the length of the indel was computed as N − M + 1. The resulting lengths were binned to give the size distribution shown in Figure 6 In the case of the indel size distribution for GD the procedure was: (i) for each gene family in our dataset (see above) we obtained the length of all indels (gaps) for all the possible alignments between the proteins in the family, and (ii) the resulting lengths were binned after a simple redundancy correction. The redundancy correction consisted of dividing the contribution of each indel in the frequency histogram by the number of sequences in the family cluster. The resulting distribution follows a power law very similar to that previously found by Benner and colleagues in a massive alignment experiment [69], supporting the reliability of our data. Both the AS and GD indels datasets were subsequently broken down in two subsets, according to whether indels were external (positioned at the N- or C-terminal ends of the protein sequence) or internal (positioned within the protein sequence). The resulting length distributions are shown in Figure 6 Overlap between indels. The procedure to estimate overlaps between AS and GD indels was: (i) map the AS indel to the sequence of the longest isoform; (ii) align the sequence of that isoform to that of the other genes in the family; (iii) map the indels from the previous alignments to the longest isoform; (iv) for each possible comparison between the AS indel and one GD indel compute the amount of common amino acids and divide it by the size of the AS indel; and (v) bin the results after redundancy correction. The redundancy correction consisted of only adding one count to the frequency histogram when the overlaps between a given AS indel and a series of GD indels were always the same. As mentioned before, the SwissProt database [44] is of high quality but small; thus, we expect to have missed a certain number of alternative splice isoforms, which are likely to increase the number of cases with high overlap between AS and GD indels. Figure S1: Distribution of GD Family Sizes Distribution of human sequences across GD families as determined by different seq.id. cutoffs (40%, 60%, 80%, 90%). GD families of size 1 denote singletons, i.e., genes without paralogues (GD−). (54 KB PPT) Click here for additional data file.(55K, ppt) Figure S2: The Distribution of Molecular Function and Biological Process We tested for functional biases across proteins with AS and/or GD using the GO annotation available for humans from the GO database [70]. For a more detailed analysis of function characteristics, see Table S3. Human genes were annotated with respect to biological process (A) and molecular function (B) using GO annotation [51,70]. GD families were determined according to an 80% seq.id. cutoff; AS family information was taken from the AltSplice database [43]. All sequences were assigned to one of the four sets, and the distribution of biological processes (A) and molecular functions (B) is shown for the four sets separately: AS−/GD− no duplication or AS known; AS−/GD+ duplicates, but no AS known; AS+/GD− no duplication, but AS known; and AS+/GD+ both duplicates and alternative splice variants known. There are no obvious biases in the function composition for any of the four constellations of AS/GD. (749 KB PPT) Click here for additional data file.(750K, ppt) Figure S3: Chromosomal Location of the Duplicated Genes We show the fraction of duplicated genes per gene family that have different chromosomal location, using a 40% seq.id. cutoff (dark red). (Data for GD80 families are not shown because of the small amount of data.) In all except one group of families, on average >55% genes within a family have different chromosomal locations. This indicates different regulation between duplicates [71] and therefore no interchangeability between AS and GD, given that transcription and mRNA splicing are tightly coupled [72,73]. (55 KB PPT) Click here for additional data file.(76K, ppt) Figure S4: Analysis for Mouse (40% seq.id. Cutoff) The four figures reproduce, for mouse, the analysis shown in Figures 3 (A) Substitutions in AS have different effects on global versus local seq.id. Light and dark green correspond to global and local seq.id. for AS substitutions, respectively. Global seq.id. is obtained after aligning two isoforms for the same gene, for which the AS event involved a substitution. Local identity applies only to the substituted stretches. Dark red corresponds to the seq.id. distribution for GD families at 40%, after sequence alignment between paralogues. The global seq.id. between splice isoforms is very high while the local seq.id. in alternative splicing variants is very low. Both seq.id. distributions for AS contrast with those of GD families. (B) Maximal mismatch distance between nonconservative substitutions is much smaller in AS than in GD. The maximal mismatch distance is the number of residues between the two most distant, nonconservative substitutions, normalized by whole sequence length. Nonconservative mismatches have a negative value in the Blosum62 matrix and were chosen for their stronger impact in protein structure and function. The plot depicts AS data in green, and GD data for families at 40% seq.id. in dark red. Substitutions in alternative splice variants are much more localized than those in gene duplicates. (C) Size distribution for indels. The AS distribution is shown in green. Indels for GD are shown for the whole-gene model (dark red). Clear differences are found between both distributions. (D) Frequency distribution of the amount of overlap between AS and GD indels, taking as reference the sequence of the AS indel (see Materials and Methods). Dark blue bars correspond to the case when indels of any size are considered. Light blue bars correspond to the case when only subdomain indels (≤30 aa) are considered. (1.1 MB PPT) Click here for additional data file.(1.1M, ppt) Figure S5: Comparison between AS, Whole-Gene, and Domain-Based GD Families To provide another definition of gene families, we estimated GD families based on domain families. We used domain annotations from the Pfam database [54] that mapped to one or several of the SwissProt [44] proteins in the AS dataset. Nonhuman sequences were removed from the alignment. (A) Global seq.id. distribution. The distribution of human AS sequences is shown in green; for GD whole-gene families (40% level) are shown in dark red; indel sizes for GD families defined by Pfam domains are shown in light red. We observe that the range of seq.id. for the latter is much lower than for AS and GD whole-gene families. At the local level (results not shown) the range of seq.id. for the Pfam model of GD is lower than that observed for AS. However, for the former the amino acid replacements spread over the whole sequence, contrary to what we observe for AS. (B) The indel size distribution of human AS sequences is shown in green. Indel sizes for GD whole-gene families (seq.id. cutoff of 40%) are shown in dark red; indel sizes for GD families defined by Pfam domains are shown in light red. In the former, whole sequences were compared within each family to obtain the indel size distribution. In the domain-based GD families, indels were obtained from the multiple sequence alignments of the Pfam databank [54] Indels for both GD models show behaviour similar to that described by Benner and colleagues [69]. (C,D) Size distributions for external and internal indels, respectively, with the same colour code as in (B). These distributions indicate that indels from Pfam domains and GD families show similar trends when compared with AS indels. Overall, our results indicate that GD and AS are in general different in their sequence/structure changes, independently of the model representing GD. (1.1 MB PPT) Click here for additional data file.(1.1M, ppt) Figure S6: Effect of Filtering Out Putative NMD Targets from the AS Data No significant differences are found between the original results and those obtained after eliminating from the AS dataset all the isoforms that may be targets of NMD machinery [61]. (A) Overall versus local seq.id. Original AS global and local seq.id. are shown in light and dark green, respectively. Overall and local seq.id. for NMD-filtered AS are shown in orange and yellow, respectively. (B) Maximal mismatch distance between nonconservative substitutions. Original AS data are shown in dark green, NMD-filtered data are shown in orange. (C) Indel size. Original AS data are shown in dark green, NMD-filtered data are shown in orange. (D) Overlap between AS and GD indels. Original data are shown in violet, dark blue, and light blue, while the corresponding NMD-filtered data are shown in yellow, orange, and light green. (1.3 MB PPT) Click here for additional data file.(1.3M, ppt) Figure S7: Excluding Potential Database Biases To exclude biases in our results introduced by the use of the SwissProt database [44] (dark green), we compared some of the findings with those obtained from using the ASAP database [62] (dark violet). The data are for human. Here we show the indel size distribution obtained using data from both databases. No obvious differences are found between the SwissProt and ASAP distributions that may affect the validity of our results. (35 KB PPT) Click here for additional data file.(36K, ppt) Figure S8: Number of Exons per Gene To obtain the number of exons per gene, we followed the procedure employed by Saxonov and colleagues to build the EID database [74]. For each sequence, we obtain the exon information from the corresponding NCBI's GenBank [75], looking at the CDS join feature. Three distributions show the number of exons per gene, corresponding to the following cases: singleton genes with AS (AS+/GD−, dark green); genes that are both duplicated and have AS (AS+/GD+, light green), and duplicated genes with no AS (AS−/GD+, dark blue). The results are obtained for gene families at both the 80% level (A) and the 40% level (B). In both cases we see that there is a trend for AS−/GD+ to have a smaller number of exons than AS+/GD+ and AS+/GD− genes. (525 KB PPT) Click here for additional data file.(526K, ppt) Figure S9: Computation of the Local Sequence Identity Between Gene Duplicates We describe the two procedures followed to compute the local seq.id. between duplicates (see Materials and Methods). (A) The first procedure is based on the use of a moving window the size, N, of the AS event. The window is moved along the aligned sequences of both duplicates, and at each position the seq.id. between them is computed (within the limits of the window). (B) In the second procedure, we first aligned the sequence of the protein with known splicing to one of its duplicates. The former was always the sequence of the SwissProt [44] reference isoform. Then, we mapped location and length of the AS substituted stretch to the sequence of the duplicate and computed seq.id. between both sequence stretches. (462 KB PPT) Click here for additional data file.(462K, ppt) Figure S10: Overview of the Expression Data Analysis (A) Illustrates the basic comparisons of coexpression, whose results are shown in Figure 2 (B) In the datasets published by Johnson et al. [17], each of the 3,840 human genes is represented by a matrix of absolute expression values of all exon junctions across 44 different tissues. We estimate AS coexpression by analyzing the variation of expression values in each gene's matrix. The average expression value of all exon junctions across the different tissues forms a vector representing the gene's overall expression pattern. For each gene family, we can produce a second matrix of gene expression patterns of the duplicates across different tissues. We estimate GD coexpression by analyzing the variation of expression values in each gene family's matrix. GD coexpression was analyzed for the dataset by Johnson et al. [17] and two conventional [53] gene expression datasets (see Table S4). We tested the following measures for analysis of coexpression. (i) The average pairwise PC. We calculated average PC between each pair of row vectors in the AS or GD matrix. PC close to 0 indicates no correlation in expression between exon junctions (representing AS) or gene duplicates, respectively. PC close to 1 indicates strong correlation between the row vectors and is indicative of little AS or differential expression amongst gene duplicates. (ii) The number of unique binarized row vectors per matrix. To normalize for the number of exon junctions per gene or number of gene duplicates in a family, we divided the number of unique row vectors by the total number of row vectors per matrix. We also tested relative entropy RE as a measure of coexpression. We calculated the relative entropy RE (mutual information) for each AS or GD matrix as the sum of pobs*log2(pobs/pexp) calculated for each column, where pobs is the observed frequency of the exon junctions or gene duplicates in one column and pexp is the expected frequency of all exon junctions or gene duplicates across all experiments. However, relative entropy did not prove to be a useful measure of matrix variation in our case, as it did not capture differential expression patterns (row vectors) but only general entropy in the matrix. While matrices in the figure show binary expression data, calculations were done on both raw and binary data. All results are similar irrespective of the cutoff for binarization (600 or 150). They are also similar irrespective of the cutoff for gene family definitions (40%, 60%, or 80% seq.id.) or of the underlying AS+ datasets employed (SwissProt or AltSplice). (746 KB PPT) Click here for additional data file.(747K, ppt) Figure S11: Anticorrelation between Family Size and Percentage of Genes with AS (66 KB PPT) Click here for additional data file.(67K, ppt) Table S1: Genomic Data Overview Provides an overview of the genomic data from the Ensembl database (human release 37.35j, mouse release 37.34e) [1] and the AS data from the AltSplice database (release 2.0 for human and mouse AS) [2], SwissProt [3], and from the Ensembl annotations. (54 KB DOC) Click here for additional data file.(55K, doc) Table S2: The Distribution of Single-Exon Genes across Human Sequences Retrotransposition produces duplicates that consist of only one exon. To test for possible bias in families of gene duplicates (GD+) stemming from retrotransposition, we examined the distribution of single-exon genes across AS and GD sets using the SEGE database [1], similar to an approach described by Kopelman and colleagues [2]. The procedure followed was: (i) all human genes were clustered according to 80% seq.id.; (ii) all genes were labelled according to their known AS; and (iii) the number of single-exon genes [1] amongst singletons, gene families, and genes with/without AS was calculated. (53 KB DOC) Click here for additional data file.(53K, doc) Table S3: Function Analysis The table lists a selection of functions as obtained from the DAVID Web server [1], for the four protein sets (AS+/GD+, AS+/GD−, AS−/GD+, AS−/GD−) derived from SwissProt (A) and AltSplice (B), using an 80% seq.id. threshold to estimate GD. A more general overview of GO functions and biological processes across the datasets is shown in Figure S2. All function annotations are significantly different from the background (E-value < 10−10). We removed redundant annotations and annotations that were too broad to be meaningful (e.g., “binding”). Duplication of particular gene families that are depleted in AS, such as ribosomal proteins or some receptors, has contributed to the inverse relationship between AS and GD, but cannot explain it completely. (96 KB DOC) Click here for additional data file.(97K, doc) Table S5: Overview of the Dataset Employed in the Protein Sequence/Structure Analysis The table shows the number of genes with AS, and the number of multiple gene families, together with the respective number of sequences. Information on AS was taken from SwissProt [1]. The data are provided for human and mouse, for 40% and 80% seq.id. clusters. (50 KB DOC) Click here for additional data file.(51K, doc) Accession Numbers The accession numbers used in this paper are from Swiss-Prot (http://www.ebi.ac.uk/swissprot): rat Piccolo C2A Q9JKS6), human MAPK9 (P45984), MAPK10 (P53779), and MAPK13 (O15264); and from the Protein Databank (http://www.rcsb.org/pdb): MAPK10 (1jnk). Acknowledgments The authors are grateful to M. Brandl, J. Castresana, C. Chothia, K. Hannay, D. Kramer, M. A. Martínez-Balbás, A. Ortiz, J. Pereira-Leal, J. Valcárcel, and C. Voelckel for helpful comments on the manuscript, and H. Dopazo, J. Dopazo, and N. L. Barbosa-Morais for useful discussions. We are grateful to the SwissProt team for their support. We thank M. Carmo-Fonseca and T. R. Pacheco for kindly providing the U2AF35 sequences from their analysis. We are grateful to the anonymous reviewers whose suggestions led to valuable additions to our work. CV acknowledges funding by the Boehringer Ingelheim Foundation, the Medical Research Council, and the International Human Frontier of Science Program. XdlC and DT acknowledge funding from the Spanish government (grant BIO2003–09327). Abbreviations
Footnotes Author contributions. CV, SAT, and XdlC conceived and designed the experiments and wrote the paper. DT, CV, and MO performed the experiments. DT, CV, MO, SAT, and XdlC analyzed the data. Funding. The authors received no specific funding for this study. Competing interests. The authors have declared that no competing interests exist. References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Science. 2000 Nov 10; 290(5494):1151-5.
[Science. 2000]Nat Genet. 2002 Jan; 30(1):29-30.
[Nat Genet. 2002]Genetics. 2002 May; 161(1):259-67.
[Genetics. 2002]J Biol Chem. 2004 Jun 25; 279(26):27039-49.
[J Biol Chem. 2004]EMBO J. 1986 Apr; 5(4):823-6.
[EMBO J. 1986]J Mol Biol. 1992 Mar 20; 224(2):461-71.
[J Mol Biol. 1992]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D235-9.
[Nucleic Acids Res. 2004]BMC Bioinformatics. 2005 Nov 7; 6():266.
[BMC Bioinformatics. 2005]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D235-9.
[Nucleic Acids Res. 2004]Mol Cell. 2004 Dec 22; 16(6):929-41.
[Mol Cell. 2004]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Genome Res. 2003 Jul; 13(7):1638-45.
[Genome Res. 2003]Curr Opin Biotechnol. 1995 Aug; 6(4):387-93.
[Curr Opin Biotechnol. 1995]EMBO J. 1986 Apr; 5(4):823-6.
[EMBO J. 1986]Hum Mol Genet. 2001 Nov 1; 10(23):2661-9.
[Hum Mol Genet. 2001]Trends Biotechnol. 2003 Aug; 21(8):346-53.
[Trends Biotechnol. 2003]J Mol Biol. 2003 Oct 31; 333(4):863-82.
[J Mol Biol. 2003]Hum Mol Genet. 2001 Nov 1; 10(23):2661-9.
[Hum Mol Genet. 2001]Trends Biotechnol. 2003 Aug; 21(8):346-53.
[Trends Biotechnol. 2003]Biochemistry. 1990 Sep 18; 29(37):8509-17.
[Biochemistry. 1990]Proc Natl Acad Sci U S A. 1995 Jan 17; 92(2):452-6.
[Proc Natl Acad Sci U S A. 1995]Hum Mol Genet. 2001 Nov 1; 10(23):2661-9.
[Hum Mol Genet. 2001]Trends Biotechnol. 2003 Aug; 21(8):346-53.
[Trends Biotechnol. 2003]Protein Eng. 1997 Jan; 10(1):7-21.
[Protein Eng. 1997]J Mol Biol. 2002 Jan 25; 315(4):771-86.
[J Mol Biol. 2002]Biochemistry. 1990 Sep 18; 29(37):8509-17.
[Biochemistry. 1990]J Mol Biol. 2002 Jan 25; 315(4):771-86.
[J Mol Biol. 2002]Trends Genet. 2003 Mar; 19(3):124-8.
[Trends Genet. 2003]Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):18920-5.
[Proc Natl Acad Sci U S A. 2005]Dev Biol. 1995 Dec; 172(2):396-411.
[Dev Biol. 1995]Nat Neurosci. 2003 Sep; 6(9):917-24.
[Nat Neurosci. 2003]EMBO J. 1986 Apr; 5(4):823-6.
[EMBO J. 1986]Bioinformatics. 2002; 18 Suppl 2():S65-73.
[Bioinformatics. 2002]Trends Biochem Sci. 2005 Sep; 30(9):515-21.
[Trends Biochem Sci. 2005]Proteins. 2004 May 1; 55(2):219-22.
[Proteins. 2004]Nat Struct Mol Biol. 2004 Jan; 11(1):45-53.
[Nat Struct Mol Biol. 2004]J Biol Chem. 2004 Jun 25; 279(26):27039-49.
[J Biol Chem. 2004]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Genetics. 2002 May; 161(1):259-67.
[Genetics. 2002]J Biol Chem. 2004 Jun 25; 279(26):27039-49.
[J Biol Chem. 2004]EMBO J. 1986 Apr; 5(4):823-6.
[EMBO J. 1986]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Nature. 2003 Jul 10; 424(6945):194-7.
[Nature. 2003]Genome Biol. 2002; 3(2):RESEARCH0008.
[Genome Biol. 2002]Adv Genet. 2002; 46():451-83.
[Adv Genet. 2002]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Nat Genet. 2005 Mar; 37(3):295-9.
[Nat Genet. 2005]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D64-9.
[Nucleic Acids Res. 2004]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2006 Jan 1; 34(Database issue):D556-61.
[Nucleic Acids Res. 2006]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Methods Enzymol. 1996; 266():554-71.
[Methods Enzymol. 1996]Bioinformatics. 2001 Mar; 17(3):282-3.
[Bioinformatics. 2001]Nucleic Acids Res. 2005 Jan 1; 33(Database issue):D476-80.
[Nucleic Acids Res. 2005]BMC Bioinformatics. 2004 Jun 2; 5():67.
[BMC Bioinformatics. 2004]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Biol. 2003; 4(5):P3.
[Genome Biol. 2003]Nat Genet. 2000 May; 25(1):25-9.
[Nat Genet. 2000]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Nucleic Acids Res. 2005 Jan 1; 33(Database issue):D562-6.
[Nucleic Acids Res. 2005]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):6062-7.
[Proc Natl Acad Sci U S A. 2004]Nucleic Acids Res. 2005 Jan 1; 33(Database issue):D562-6.
[Nucleic Acids Res. 2005]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D64-9.
[Nucleic Acids Res. 2004]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Bioinformatics. 2001 Mar; 17(3):282-3.
[Bioinformatics. 2001]Nucleic Acids Res. 2002 Jan 1; 30(1):276-80.
[Nucleic Acids Res. 2002]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Hum Mol Genet. 2001 Nov 1; 10(23):2661-9.
[Hum Mol Genet. 2001]Trends Genet. 2003 Mar; 19(3):124-8.
[Trends Genet. 2003]Proc Natl Acad Sci U S A. 2005 Dec 27; 102(52):18920-5.
[Proc Natl Acad Sci U S A. 2005]Bioinformatics. 2002; 18 Suppl 2():S65-73.
[Bioinformatics. 2002]J Mol Biol. 1970 Mar; 48(3):443-53.
[J Mol Biol. 1970]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]J Mol Biol. 1970 Mar; 48(3):443-53.
[J Mol Biol. 1970]J Mol Biol. 2004 Jan 9; 335(2):495-502.
[J Mol Biol. 2004]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Proc Natl Acad Sci U S A. 1992 Nov 15; 89(22):10915-9.
[Proc Natl Acad Sci U S A. 1992]Nat Genet. 1999 Jul; 22(3):231-8.
[Nat Genet. 1999]Structure. 1998 Aug 15; 6(8):983-91.
[Structure. 1998]J Mol Biol. 1970 Mar; 48(3):443-53.
[J Mol Biol. 1970]J Mol Biol. 1993 Dec 5; 234(3):779-815.
[J Mol Biol. 1993]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]J Mol Biol. 1993 Feb 20; 229(4):1065-82.
[J Mol Biol. 1993]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D258-61.
[Nucleic Acids Res. 2004]Nat Genet. 2000 May; 25(1):25-9.
[Nat Genet. 2000]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D258-61.
[Nucleic Acids Res. 2004]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D64-9.
[Nucleic Acids Res. 2004]Mol Biol Evol. 2006 Sep; 23(9):1715-23.
[Mol Biol Evol. 2006]Nature. 2002 Apr 4; 416(6880):499-506.
[Nature. 2002]Nature. 2002 Jul 11; 418(6894):236-43.
[Nature. 2002]Nucleic Acids Res. 2002 Jan 1; 30(1):276-80.
[Nucleic Acids Res. 2002]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2002 Jan 1; 30(1):276-80.
[Nucleic Acids Res. 2002]J Mol Biol. 1993 Feb 20; 229(4):1065-82.
[J Mol Biol. 1993]Genome Biol. 2004; 5(2):R8.
[Genome Biol. 2004]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2003 Jan 1; 31(1):101-5.
[Nucleic Acids Res. 2003]Nucleic Acids Res. 2000 Jan 1; 28(1):185-90.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2006 Jan 1; 34(Database issue):D16-20.
[Nucleic Acids Res. 2006]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):6062-7.
[Proc Natl Acad Sci U S A. 2004]Genomics. 2005 Aug; 86(2):127-41.
[Genomics. 2005]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D64-9.
[Nucleic Acids Res. 2004]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):6062-7.
[Proc Natl Acad Sci U S A. 2004]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Science. 2000 Nov 10; 290(5494):1151-5.
[Science. 2000]Science. 2003 Jun 13; 300(5626):1701-3.
[Science. 2003]Cell. 2000 Jun 9; 101(6):573-6.
[Cell. 2000]Science. 2000 Nov 10; 290(5494):1151-5.
[Science. 2000]Science. 2003 Jun 13; 300(5626):1701-3.
[Science. 2003]Science. 2000 Nov 10; 290(5494):1151-5.
[Science. 2000]Science. 2000 Nov 10; 290(5494):1151-5.
[Science. 2000]J Biol Chem. 2004 Jun 25; 279(26):27039-49.
[J Biol Chem. 2004]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D64-9.
[Nucleic Acids Res. 2004]Bioinformatics. 2001 Mar; 17(3):282-3.
[Bioinformatics. 2001]Nat Genet. 2005 Jun; 37(6):588-9.
[Nat Genet. 2005]Genome Res. 2006 Feb; 16(2):182-9.
[Genome Res. 2006]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Proc Natl Acad Sci U S A. 2004 Apr 20; 101(16):6062-7.
[Proc Natl Acad Sci U S A. 2004]Nucleic Acids Res. 2004 Jan 1; 32(Database issue):D64-9.
[Nucleic Acids Res. 2004]Science. 2003 Dec 19; 302(5653):2141-4.
[Science. 2003]Nucleic Acids Res. 2000 Jan 1; 28(1):45-8.
[Nucleic Acids Res. 2000]Bioinformatics. 2001 Mar; 17(3):282-3.
[Bioinformatics. 2001]Proc Natl Acad Sci U S A. 1992 Nov 15; 89(22):10915-9.
[Proc Natl Acad Sci U S A. 1992]Int J Pept Protein Res. 1988 Oct; 32(4):269-78.
[Int J Pept Protein Res. 1988]